DSS Receives New York Stock Exchange Notice Regarding Late Form 10-Q Filing
30 août 2022 16h45 HE
|
DSS, Inc.
ROCHESTER, N.Y., Aug. 30, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating businesses within nine divisions and strategically acquiring and developing...
Impact BioMedical Develops Quantum Antihistamine
26 juil. 2022 08h00 HE
|
DSS, Inc.
ROCHESTER, N.Y., July 26, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating businesses within nine divisions and strategically acquiring and developing...
DSS Announces Licensing of Impact BioMedical’s Linebacker Portfolio to ProPhase Labs
21 juil. 2022 17h00 HE
|
DSS, Inc.
ROCHESTER, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating businesses within nine divisions and strategically acquiring and developing...
DSS Strengthens and Expands Board with Appointment of Two Independent Directors
13 juil. 2022 08h00 HE
|
DSS, Inc.
ROCHESTER, N.Y., July 13, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating businesses within nine divisions and strategically acquiring and developing...
Impact BioMedical Announces License Agreement with ProPhase Labs to Produce and Distribute Viral-Fighting Compound Equivir
28 juin 2022 08h00 HE
|
DSS, Inc.
HENRIETTA, N.Y., June 28, 2022 (GLOBE NEWSWIRE) -- Impact Biomedical, Inc., a wholly owned subsidiary of DSS, Inc. (NYSE American: DSS), along with its scientific research partner Global Research...
DSS’s Impact BioMedical Receives China Patent for its Functional Fragrance Formulation Mosquito Repellant
07 juin 2022 07h00 HE
|
DSS, Inc.
HENRIETTA, N.Y., June 07, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (“DSS” or the “Company”) (NYSE American: DSS), a multinational company operating businesses within nine divisions and strategically...
DSS, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report®
06 mai 2022 08h30 HE
|
DSS, Inc.
ROCHESTER, N.Y., May 06, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating businesses within nine divisions and strategically acquiring and developing assets...
Impact BioMedical’s Proprietary Equivir Compound to Treat Viral Infection Receives Clean Patentability Report from World Intellectual Property Organization’s ISA Division
03 mars 2022 08h00 HE
|
DSS, Inc.
ROCHESTER, N.Y., March 03, 2022 (GLOBE NEWSWIRE) -- Impact Biomedical, Inc., a wholly owned subsidiary of DSS, Inc. (NYSE American: DSS), along with its scientific research partner Global Research...
CORRECTION - DSS Announces Letter to Shareholders
28 févr. 2022 17h15 HE
|
DSS, Inc.
ROCHESTER, N.Y., Feb. 28, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by DSS, Inc. (NYSE American: DSS), please note that in paragraph fourteen, [With more...
DSS Announces Letter to Shareholders
28 févr. 2022 08h00 HE
|
DSS, Inc.
ROCHESTER, N.Y., Feb. 28, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (“DSS” or the “Company”) (NYSE American: DSS), a multinational company with ten operating business lines in diverse, high-growth...